Príjmy spoločnosti Cellectis

Aká je hodnota metriky Príjmy spoločnosti Cellectis?

Hodnota metriky Príjmy spoločnosti Cellectis je -$113.27

Aká je definícia metriky Príjmy?

Výsledok príjmov pre kmeňových akcionárov (Income) sa rovná celkovému príjmu mínus vyplatené prioritné dividendy.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Príjmy spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Cellectis

Čomu sa venuje spoločnosť Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Firmy s metrikou príjmy podobnou spoločnosti Cellectis